← FDA DRUG APPROVALS

FDA ANDA · ANDA076019

DEFEROXAMINE MESYLATE

Sponsor: HOSPIRA

APPLICATION
ANDA076019
TYPE
ANDA
ORIGINAL APPROVAL
2004-03-17
LATEST ACTION
2025-05-08
ROUTE
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DEFEROXAMINE MESYLATEPrescription
DEFEROXAMINE MESYLATE 2GM/VIAL · INJECTABLE · INJECTION
DEFEROXAMINE MESYLATEPrescription
DEFEROXAMINE MESYLATE 500MG/VIAL · INJECTABLE · INJECTION

Approval history

2025-05-08Labeling · Supplement 30 · standardAP
2023-10-23Labeling · Supplement 20 · standardAP
2023-10-23Labeling · Supplement 27 · standardAP
2016-11-08Labeling · Supplement 14 · standardAP
2009-12-03Labeling · Supplement 11AP
2007-12-14Labeling · Supplement 8AP
2004-03-17OriginalReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →